Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Oncology department celebrates 50 years of excellence
2017-09-07

  Description: Oncology photo Tags: Oncology, cancer, University of the Free State, UFS, Dr Alicia Sherriff, Faculty of Health Sciences

The UFS Department of Oncology celebrated 50 years of
existence. Prof Louis Goedhals says that the department
is like a family that will carry and support you.
Photo: Wendy Ruth
 



South Africa could see an increase of 78% in the number of cancer cases by 2030 and from a global perspective, a 75% increase is expected, increasing the total incidence of all new cancer cases from 12.7 million in 2008 to 22.2 million by 2030, according to a recent study published by medical journal Lancet. According to the Cancer Association of South Africa (CANSA), more than 100 000 South Africans are diagnosed each year. It is rather comforting that the University of the Free State’s (UFS) Faculty of Health Sciences has an Oncology department that has been fighting cancer for 50 years. 

Excellence over the decades 
The 50-year celebration of the Department of Oncology took place at the UFS Centenary Complex on the Bloemfontein Campus on 19 August 2017. The auspicious event was attended by UFS Faculty of Health Sciences registrars, radiation oncology radiographers and professional nurses who had trained in the department over the past 50 years, as well as the current departmental staff.

Dr Alicia Sherriff, Head of the Department of Oncology welcomed the dignitaries and thanked everyone for their attendance and dedication to the department, Prof Louis Goedhals, the oldest surviving head of department, gave a summary of the 50 years. He said once you were involved with this department you became part of a family that would carry and support you. Memories were shared and friendships rekindled. The message of this department that stood the test of time was: “To cure sometimes, to relieve often, to comfort always … and to bring hope”.

UFS dignitaries reveled in the moment 

Among the special guests were the Rector and Vice Chancellor, Prof Francis Petersen, Prof Gert van Zyl, Dean of Faculty of Health Sciences; the Free State MEC for Health Mr Butana Komphela, and CEO of Universitas Hospital Dr Marcus Molokomme, were invited. The function was well attended by personnel, graduates from as far as Portugal, and dignitaries from the university. There was a sense of unity and belonging among all the attendees and enthusiastic catching up over the years that have passed.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept